Friday, 19 Jul 2019

You are here

Low Remission/LDA Rates with TNF inhibitors in Rheumatoid Arthritis


Analysis of Rheumatoid Arthritis patients enrolled and treated as part of the British Society for Rheumatology Biologics Registry shows that sustained remission or low disease activity state (LDA) on TNF inhibitor treatment is uncommon and that combing methotrexate with an anti-TNF increases the odds of sustained remission/LDA.

The registry enrolled 14,436 RA patients initiating their first TNFi (between 2001 and 2013) with most starting etanercept, infliximab and adalimumab.  Therapeutic choices were at the descretion of the treating physician and disease assessments were done periodically to calculate the 28-joint DAS (DAS28) scores.  RA remission and LDA was defined as achieving the required DAS28-ESR thresholds on two sequential follow-ups (eg, > 6 months) during the first 3 years of data collection. 

Only 15% of RA patients achieved sustained remission and only 26% achieved sustained LDA.

Predictors of sustained remission/LDA included:

  • Adalimumab moreso than etanercept
  • Higher patient global assessment scores
  • Non-smokers (never- and ex-smoker) compared to current smoking
  • Higher swollen joint counts
  • Combined MTX plus anti-TNF

Negative predictors of sustained remission and LDA included:

  • Poor baseline functional status (HAQ)
  • Females
  • Older age at starting anti-TNF
  • Infliximab use 
  • Higher BMI
  • Higher baseline ESR
  • (Higher tender joint counts were negatively associated with sustained LDA only).

The good news is that the number of RA patients achieving sustained remission and LDA increased significantly over time - remission from 14.3-14.9% (2001-2010) to 21.6% (2010-2013), but so did MTX use (56% in 2001–2010 subgroup to 64% in 2010–2013 subgroup). 

During this study period (2001-2013) the time from first rheumatologist consultation to commencement of anti-TNF decreased from 10 to 6 years (P < 0.01). 

The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

“During the study period ... time from first rheum. consult. to commencement of anti-TNF decreased from 10 to 6 years.” Seriously? On which planet? Is this a group of SSZ or MTX super-responders? Wow.

More Like This

Upadacitinib Superior to Adalimumab in Methotrexate Refractory RA

Upadacitinib, a JAK1-selective inhibitor, was studied head to head against adalimumab and placebo in rheumatoid arthritis after an inadequate response to methotrexate, and shown to be superior to ADA and PBO in ACR20 and DAS remission level responses.

CRP Utility in COPD Exacerbations

NEJM reports on the utility of C-reactive protein (CRP) testing in chronic obstructive pulmonary disease (COPD) patients, showing that CRP guided prescribing of antibiotics for exacerbations of COPD in primary care clinics resulted in a lower percentage of patients who reported antibiotic use.

EULAR 2019 - Day 1 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Here are a few of the highlights from day 1 EULAR in Madrid, including another IL-23 inhibitor, BTK inhibition, abatacept in Sjogren's syndrome, don't repeat the ANA, and drug free remission in systemic JIA.

Borrelia burgdorferi Peptidoglycan Shedding Drives Lyme Arthritis

Research published in PNAS has shown that long after active Lyme infection in the joint, a peptidoglycan (PG) of the the spirochete Borrelia burgdorferi can be found in the joints of those with late-stage Lyme disease.


EULAR 2019 - Day 1 Report

Here are a few of the highlights from day 1 EULAR in Madrid.